上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Bupranolol 纯度: 99.44%
Bupranolol 是一种口服活性、竞争性和非选择性 β-adrenoceptor 拮抗剂,无固有的拟交感神经活性。
Bupranolol Chemical Structure
CAS No. : 14556-46-8
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
25 mg | ¥6900 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
Bupranolol 相关产品
•相关化合物库:
- Drug Repurposing Compound Library Plus
- FDA-Approved Drug Library Plus
- Bioactive Compound Library Plus
- GPCR/G Protein Compound Library
- Immunology/Inflammation Compound Library
- Neuronal Signaling Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Drug Repurposing Compound Library
- Orally Active Compound Library
- Neurotransmitter Receptor Compound Library
- FDA Approved & Pharmacopeial Drug Library
- Anti-Alzheimer’s Disease Compound Library
- Neurodegenerative Disease-related Compound Library
生物活性 |
Bupranolol is an orally active, competitive and non-selective β-adrenoceptor antagonist without intrinsic sympathomimetic activity[1]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target[1] |
|
||||||||||||||||
体外研究 (In Vitro) |
Bupranolol (1~3 μM) shifts isoprenaline-induced relaxation in the presence of 30 μM propranolol. Bupranolol acts as a competitive antagonist of isoprenaline-induced relaxation in the presence of 300 nM propranolol, with a pA2 value of 5.90. Bupranolol antagonizes β1– and β2-ARs with pA2 values of ≈9.0, and also antagonizes β3-AR with a pA2 value of 6.0[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
271.78 |
||||||||||||||||
Formula |
C14H22ClNO2 |
||||||||||||||||
CAS 号 |
14556-46-8 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 50 mg/mL (183.97 mM; ultrasonic and warming and heat to 60°C) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务